Saxenda

What is Saxenda?

Saxenda is a prescription injectable medication containing liraglutide, manufactured by Novo Nordisk and FDA-approved on December 23, 2014, under new drug application number 206321 for chronic weight management in adults. It was the first GLP-1 receptor agonist approved specifically for obesity, predating both Wegovy (semaglutide) and Zepbound (tirzepatide). The label was expanded in December 2020 to include adolescents aged 12 to 17 with body weight over 60 kg and a BMI corresponding to obesity in adults. Saxenda is administered as a once-daily subcutaneous injection and is the same active ingredient as Victoza, marketed at a higher maintenance dose (3 mg daily versus 1.8 mg for Victoza) specifically for weight management. Saxenda's role in the modern GLP-1 landscape has shifted as weekly semaglutide and tirzepatide products have emerged with larger weight-loss effects and less frequent dosing, but it remains an option for patients who prefer daily titration, have insurance that preferentially covers liraglutide, or have tolerated liraglutide well previously.

How Saxenda works

Saxenda works by mimicking GLP-1, a naturally occurring incretin hormone released by the intestine after meals. Liraglutide binds to the GLP-1 receptor and produces four coordinated effects: it stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the hypothalamus to reduce hunger and increase satiety. Unlike the weekly agents semaglutide and tirzepatide, liraglutide has a half-life of approximately 13 hours, which is why it requires daily dosing to maintain steady drug exposure. The daily schedule gives patients more flexibility to adjust if side effects emerge — a forgotten or delayed dose has less downstream impact than missing a weekly injection — but it also imposes a higher adherence burden over time. The 3 mg Saxenda dose is specifically calibrated for appetite-suppressing effect in patients with obesity, compared to the 1.2 or 1.8 mg Victoza dose calibrated primarily for glycemic control. This dose-response relationship is consistent across liraglutide clinical trials — higher doses produce stronger satiety signals and greater weight reduction.

Who Saxenda is for

Saxenda is FDA-approved for chronic weight management in two patient populations:

• Adults with obesity (BMI ≥ 30 kg/m²) — as an adjunct to reduced-calorie diet and increased physical activity.
• Adults with overweight (BMI ≥ 27 kg/m²) who also have at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea.
• Adolescents aged 12 to 17 with body weight over 60 kg and BMI corresponding to obesity in adults.

Before prescribing Saxenda, your clinician will evaluate BMI, comorbidities, previous weight-management attempts, kidney function, history of pancreatitis or gallbladder disease, any personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and insurance coverage. Saxenda is not FDA-approved for type 1 diabetes, for type 2 diabetes in adults (Victoza is the liraglutide product for diabetes), or for use during pregnancy or breastfeeding. Insurance coverage for Saxenda varies widely — weight-management medications are frequently excluded or subject to prior authorization, though Saxenda has been on insurance formularies longer than newer weight-loss agents, which sometimes works in its favor for coverage.

How to take Saxenda

Saxenda is administered as a subcutaneous injection once daily, at any time of day, with or without food. Most patients find it easiest to pick a specific time — often morning with coffee or evening before bed — and stick to it for consistency. The injection is given into the abdomen, thigh, or upper arm, rotating sites between doses. The Saxenda pen is reusable and uses disposable needles; use a new needle for each injection and never share a pen between individuals even if the needle is changed.

The titration schedule is weekly rather than monthly because of liraglutide's shorter half-life: 0.6 mg daily for one week, then 1.2 mg daily for one week, then 1.8 mg daily for one week, then 2.4 mg daily for one week, then 3.0 mg daily as the maintenance dose. The starter doses are not therapeutic for weight loss — they exist to let the body adjust and minimize early gastrointestinal side effects. The FDA prescribing information advises discontinuation if a patient has not lost at least 5 percent of baseline body weight by 12 weeks on the 3.0 mg maintenance dose, as responders can usually be identified within this window. Your prescriber may extend time at a given step if side effects are bothersome, but doses below 3.0 mg are not maintenance doses.

If you miss a dose and it is within 12 hours of your usual injection time, take it as soon as you remember. If more than 12 hours have passed, skip the missed dose and resume your regular schedule the next day. Do not take two doses to make up for a missed one. If you miss three or more consecutive days, contact your prescriber; you may need to restart the titration at a lower dose. Store unopened pens in the refrigerator between 36°F and 46°F (2-8°C). After first use, pens can be kept at room temperature (up to 86°F / 30°C) or refrigerated for up to 30 days.

Side effects of Saxenda

Saxenda's side effect profile is typical of GLP-1 receptor agonists, with gastrointestinal effects dominant during the weekly titration period. All frequencies below come from the SCALE clinical trial program pooled data in the FDA prescribing information.

Common side effects (worst during titration, typically improving over the first 4 to 8 weeks):

• Nausea — reported in approximately 39 percent of patients, peaking in the first two weeks
• Diarrhea — 21 percent
• Constipation — 19 percent, can persist longer than other GI effects
• Vomiting — 16 percent, more frequent during early titration
• Hypoglycemia — 23 percent in patients with type 2 diabetes on concurrent insulin or sulfonylureas; less common in patients without diabetes
• Injection site reactions — 14 percent, typically minor
• Headache — 14 percent
• Fatigue — 11 percent
• Decreased appetite — expected therapeutic effect but can be excessive in some

Less common but serious adverse events requiring prompt medical attention:

• Acute pancreatitis (less than 1 percent) — severe, persistent upper abdominal pain radiating to the back
• Gallbladder events (cholelithiasis, cholecystitis, about 2 percent) — risk rises with any rapid weight loss
• Acute kidney injury — secondary to dehydration from persistent GI effects
• Serious allergic reactions — anaphylaxis and angioedema reported post-marketing
• Suicidal ideation or depression — monitored in SCALE trials; small numerical imbalances versus placebo observed
• Heart rate increase — mean heart rate increases by 2 to 3 beats per minute on treatment

Management strategies — slow or pause titration (stay an extra week at each step if needed), eat smaller meals, avoid high-fat or very spicy foods during dose increases, stay well hydrated, and limit alcohol. Contact your prescriber for severe abdominal pain, persistent vomiting, signs of dehydration, vision changes, difficulty breathing, mood changes, or any rapid new symptom.

Who should not take Saxenda

Saxenda is contraindicated for patients with any of the following:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to liraglutide or any component of the formulation

Boxed warning: Liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in rodent studies. Whether this risk extends to humans is unknown. Patients should be counseled to report any persistent neck mass, difficulty swallowing, shortness of breath, or unexplained hoarseness.

Additional caution is appropriate for patients with a history of pancreatitis, severe gastroparesis or other significant gastrointestinal motility disorder, significant kidney impairment (volume depletion from GI effects can worsen renal function), pre-existing diabetic retinopathy, pregnancy or plans to become pregnant (discontinue before a planned pregnancy), or breastfeeding. Because Saxenda slows gastric emptying, the absorption of orally administered medications may be affected — review oral contraceptives, thyroid hormone, warfarin, and time-critical cardiovascular drugs with your pharmacist. Concurrent use with other GLP-1 receptor agonists (including Victoza — which contains the same active ingredient at a different dose — as well as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Byetta, Bydureon, Foundayo) is not recommended.

What to expect on Saxenda

The Saxenda experience is paced differently from weekly GLP-1 agents — titration is faster (one week per step versus four) but maintenance and response are similar in character.

Week 1 to week 5 (titration from 0.6 mg to 3.0 mg). Appetite suppression builds noticeably with each weekly dose increase. GI side effects tend to be strongest during the first two weeks and during any step the patient advances too quickly. By the end of titration, most patients report meaningful changes in hunger and portion sizes. Weight loss during this five-week titration averages 2 to 3 kg.

Month 2 to month 3 (3.0 mg maintenance). Blood sugar and weight begin to change measurably. Mean weight loss at 12 weeks in SCALE was approximately 5 percent of baseline body weight. The FDA label includes the 12-week checkpoint — patients who have not lost at least 5 percent of baseline by this point are unlikely to respond long-term and discontinuation is recommended.

Month 3 to month 12. For responders, weight loss continues to accumulate at a decelerating rate. At 56 weeks in SCALE Obesity and Prediabetes, mean weight loss was approximately 8.4 kg (8 percent of baseline body weight); roughly a third of patients lost 10 percent or more. Blood pressure typically drops, lipid profiles improve, and many patients with prediabetes see normalization of fasting glucose.

Beyond 12 months. Patients who sustain Saxenda at the 3 mg maintenance dose typically sustain their weight loss; those who discontinue regain the majority of lost weight within one year. Your prescriber will schedule follow-up every three to six months to monitor weight, cardiometabolic labs, and tolerability. For patients who do not achieve their weight-loss goals on Saxenda, switching to semaglutide-based Wegovy or tirzepatide-based Zepbound is a common next step, as both have produced larger mean weight loss in trials.

Saxenda cost and coverage

The list price of Saxenda is approximately $1,349 per five-pen pack (one month of therapy at the 3 mg maintenance dose, accounting for titration usage during the first weeks) before insurance, based on the Novo Nordisk wholesale acquisition cost. There is no FDA-approved generic version yet, though liraglutide patents began expiring in 2024 in some markets, and generic or biosimilar competition is anticipated.

What you actually pay depends heavily on coverage:

• Commercial insurance for obesity: Some plans cover Saxenda for patients with documented obesity, typically with prior authorization. Copays commonly range from $25 to $200 per month. Many plans exclude weight-loss drugs entirely.
• Medicare Part D: Currently does not cover Saxenda for weight loss under federal law.
• Medicaid: Coverage varies dramatically by state; some states cover Saxenda under obesity care benefits.
• Manufacturer savings: The Novo Nordisk Saxenda Savings Card can reduce eligible commercially-insured patients' copay to as low as $25 per month for up to 24 months; not available to Medicare or Medicaid beneficiaries.
• Patient assistance: Uninsured patients meeting income criteria may qualify for the Novo Nordisk Patient Assistance Program, which can provide the medication at no cost.
• Generic or biosimilar outlook: With liraglutide patent protection eroding, lower-cost generic liraglutide products are expected to enter the market in the coming years, which could significantly reduce out-of-pocket costs for this medication.

Check your specific plan's coverage, prior-authorization rules, and the current Novo Nordisk savings program before filling — weight-management drug coverage terms change frequently.